ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
Part of paid clinical trials in Charlotte, North Carolina.
- Sponsor
- Wake Forest University Health Sciences
- Study ID
- NCT06945042
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 64 Years
- Healthy Volunteers
- Not accepted
Interventions
- Arm A — OTHERThe intervention will consist of systematic financial navigation with consistent screening and intervention on any financial related issues. All patients randomized to the financial navigational group will be contacted by clinical trial staff assigned to the study to screen for financial needs. Based on the results of this assessment, the clinical trials staff will refer to the appropriate services for personalized recommendations and assistance provided by Atrium Health personnel including financial navigators, nurse navigators. All the resources provided to the patient, including counseling, will be free of charge. Assessment will be performed once per month for 6 months.
- Arm B — OTHERAll patients randomized to the Standard of Care arm will have access to the financial distress resources (Financial Navigation and Nurse Navigation) as per current clinical policy which is per patient or clinician request. Utilization of these resources will be tracked to assess and describe the per-protocol population. All the resources provided to the patient, including counseling, will be free of charge as per institutional policy.
Study Details
The purpose of this research is to see how personal financial burden (financial toxicity) related to cancer affects the overall health and quality of life by evaluating the impact of systematic financial navigation in addition to standard financial distress interventions during cancer treatment.
Key Dates
- Start date
- Jun 27, 2025
- Status verified
- Feb 2026
- Primary completion
- May 31, 2028
- Completion
- May 31, 2028
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Other: Systematic Financial NavigationParticipants randomized to Arm A will initiate navigation as soon as feasibly possible after randomization but no later than 4 weeks from enrollment. The intervention will consist of systematic financial navigation with consistent screening and intervention on any financial related issues. The clinical trials staff will refer the participant to the appropriate services for personalized recommendations and assistance provided by Atrium Health personnel including financial navigators, nurse navigators. All the resources provided to the patient, including counseling, will be free of charge. Assessment will be performed once per month for 6 months.
- Other: Standard of Care Financial Distress InterventionParticipants randomized to Arm B will receive standard of care financial distress treatment including nurse navigation and pharmacy resources as soon as feasibly possible after randomization but no later than 4 weeks from enrollment. All patients randomized to the Standard of Care arm will have access to the financial distress resources (Financial Navigation and Nurse Navigation) as per current clinical policy which is per patient or clinician request. All the resources provided to the patient, including counseling, will be free of charge as per institutional policy.
Primary Outcome Measure
Self-reported financial toxicity as assessed by the total score of the COmprehensive Score Financial Toxicity (COST) assessment tool at 6 months after enrollment. [ Time Frame: From the date of randomization up until six months ]
Central Contacts
- Courtney Schepel(980) 442-2327
- Thomas Knight, MD(980) 442-4363
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Levine Cancer Insitute | Charlotte | North Carolina | 28204 | Courtney Schepel Thomas Knight, MD (PRINCIPAL_INVESTIGATOR) |
| Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem | North Carolina | 27103 |
Find similar trials in Charlotte, NC
By condition
By specialty
Related Studies
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationPHASE1/PHASE2 · Recruiting · Syndax Pharmaceuticals · Duarte, California
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)PHASE2/PHASE3 · Recruiting · Taiho Oncology, Inc. · Los Angeles, California
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPHASE3 · Recruiting · Children's Oncology Group · Birmingham, Alabama
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyPHASE1/PHASE2 · Recruiting · PedAL BCU, LLC · Birmingham, Alabama